Diabetes

View All

recent-pharma-news
AbbVie, Sofinnova back; Gilead, Kite ink; Biogen aims filing; Reversing diabetes

AbbVie, Sofinnova back USD 38 Million for Nitrome Biosciences Nitrome Biosciences contemplates treating Parkinson's disease and diabetes by targeting a new class of enzymes. The pharma raised USD 38 million from the Sofinnova Partners and AbbVie Ventures. The San Francisco-based biotech is focusing at a famil...

Find More

Telemedicine
Telemedicine: Can it be the future of healthcare?

Telemedicine is one of the fastest-growing domains in the healthcare industry. Telemedicine is the practice of providing healthcare services like evaluation, diagnosis and treatment to the patients using telecommunication technology where both the healthcare provider and patient are present at different locations. ...

Find More

Bioelectronic Medicine
Bioelectronic Medicine: Applications and Future Prospects

Healthcare industry during the past few decades has witnessed phenomenal growth and improvement due to technological advancement and innovation. The hospital management, medical devices & equipment, pharmaceutical products, and surgical procedures all have gone under tremendous up-gradation and improvement.&nbs...

Find More

Dubai healthcare
Dubai: A leading and exciting pharma hotspot

The dream of the UAE government to place its capital city among the best cities in the world has led to the introduction of ‘Dubai plan 2021’, focused on transforming into a smart city through an investment of more than USD 7 Billion. Dubai’s smart city strategy includes over 100 initiatives, which aims at fosterin...

Find More

Healthcare scenario in MENA region
Booming Healthcare sector in MENA: Lucrative opportunity for Global pharma players

The Middle-East and North-Africa region (MENA), which encompasses some of the world’s wealthiest economies, extends unparalleled opportunities to multinational corporations with expertise in medical devices. There is a conspicuous disparity in the economic prowess across the countries, but most of them have shown r...

Find More

Cardiovascular Disease
Cardiovascular Disease: A major cause of health loss and a global burden

Cardiovascular diseases (CVDs) are one of the leading causes of death and health loss in people in the US. As per a study by the National Vital Statistics Report, every 37 seconds, one person dies of Cardiovascular diseases in the US.  Cardiovascular diseases also known as heart disease, encompasses a wide range...

Find More

Digital therapeutics
Potential of Digital therapeutics and increasing CVDs

The 21st century has been a remarkable century for humankind, as a lot of innovation, research and development has taken place in the field of healthcare, due to which we have been able to increase the overall lifespan of the human beings.  However, the central question is, are we able to increase the healt...

Find More

World Diabetes Day
World Diabetes Day | 2019

World Diabetes Day, observed on 14 November every year, aiming to raise awareness about the impact that diabetes has on the family. This year, the theme this day is Family and Diabetes. World Diabetes Day  According to a survey by WHO, 425 million people are still struggling with diabetes, and by th...

Find More

First oral GLP-1 treatment approved for type2 Diabetes

The US FDA has approved Rybelsus (semaglutide) oral tablets to improve blood sugar in adult patients with Type II Diabetes. Rybelsus is an oral glucagon-like peptide (GLP-1) receptor protein treatment which has been approved after 15 years of the approval first GLP-1 agonist. GLP-1 is a hormone found in insuffi...

Find More

Pharma News
Fujifilm acquires global rights to Cynata’s novel therapy for GvHD; Themis raises EURO 40 million for Chikungunya vaccine; Bayer to license One Drop’s digital diabetes platform

FUJIFILM Corporation has signed an exclusive licensing agreement with an Australian bio-venture Cynata Therapeutics Limited for CYP-001. Under the agreement, FUJIFILM will gain rights to develop, manufacture and market a drug for the treatment of graft-versus-host disease (GvHD). CYP-001 is a Cynata’s lead cand...

Find More